Communiqué Archives - Insights
April 22, 2017, is the 47th anniversary of Earth Day, a worldwide celebration of events held to demonstrate support for environmental protection. The mission and efforts of Earth Day are significant to Mayo Clinic, where environmental sustainability is at the forefront in its practice of medicine.
Blood transfusion is the most common procedure performed in hospitals in the U.S. Yet published evidence shows significant gaps in clinicians’ knowledge of this critical aspect of patient care, including possible adverse reactions that can occur after blood transfusion. James Stubbs, M.D.; Daryl Kor, M.D.; and Justin Kreuter, M.D., offer five steps for improving the safety and efficacy of the transfusion-medicine practice.
Laboratories face increasing pressure to automate their operations as they are challenged by a continuing increase in workload, a need to reduce expenditure, and a demand for accuracy and improved turnaround time—essentially doing more with less. Mayo Medical Laboratories implemented a sort automation system to ensure continuous testing operations while improving turnaround time, decreasing laboratory errors, and increasing accuracy and throughput.
Greg Widseth was suddenly hit by a rare disease that prompted his immune system to attack his brain cells, resulting in as many as 60 seizures a day. Special blood and spinal fluid tests developed by Mayo Medical Laboratories confirmed that Widseth had antibodies known to target certain brain cells.
Recently, a team of researchers and physicians at Mayo Clinic in Rochester identified a new type of renal amyloidosis derived from the protein apolipoprotien C-II (Apo-CII).
Myelodysplastic syndromes (MDS) are malignant hematopoietic stem cell disorders categorized under chronic myeloid malignancies. In this publication, we share our 25 years of experience with primary MDS patients who were evaluated and treated at Mayo Clinic.
Helicobacter pylori (H pylori) infection is among the most common bacterial infections worldwide with approximately one-half of the world’s population infected. Several invasive and noninvasive testing methods are available to detect H pylori infection.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel biomarker of atherosclerosis and is often referred to by the trademark name “The PLAC Test.” Lp-PLA2 is an enzyme involved with atherosclerotic plaque formation and elevations in plasma Lp-PLA2 concentration and activity are associated with increased risk of cardiovascular disease.
Accurate matching of patients with appropriate blood units is imperative for safe blood transfusion practice. In theory, a computerized bar code-based blood identification system should result in a reduction in transfusion errors.
Inherited cardiovascular diseases have historically been identified most frequently through the patient’s family history. Now, next-generation sequencing technology has taken genetic testing to a new level, allowing assessment of multiple genes and mutations with one test.
Serum thyroglobulin concentrations are used to monitor patients with differentiated thyroid cancer, but may be misleading in the presence of antithyroglobulin autoantibodies and heterophile antibodies. Mayo Medical Laboratories has developed an assay to address this issue by testing first for the presence of thyroglobulin antibodies by immunoassay and, in antibody-positive specimens.
The porphyrias are a group of inborn errors of metabolism caused by enzymatic defects in the heme biosynthetic pathway. Depending upon the specific type of porphyria suspected, certain tests are more informative than other assays.